FinTrade Sherpa, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that FinTrade Sherpa, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $0 | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | $0 | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Mar 27, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Mar 27, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Mar 27, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Mar 30, 2017 |
| FY2015 | Dec 31, 2014 | $0 | Aug 11, 2016 |
| FY2014 | Dec 31, 2013 | $0 | Mar 25, 2015 |
| FY2011 | Dec 31, 2011 | $0 | Apr 13, 2012 |
| FY2011 | Dec 31, 2010 | $0 | Apr 13, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($341.9K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($79.1K) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($62.9K) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $2.03M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($2.57M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($493.6K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($296.9K) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($332.6K) | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | ($691.6K) | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | ($268.1K) | Mar 27, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($62.9K) | Mar 22, 2024 |
| FY2023 | Dec 31, 2022 | ($155.5K) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($309.3K) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($355.7K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($231.8K) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($273.4K) | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | ($646.0K) | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | ($234.4K) | Mar 27, 2018 |
| FY2016 | Dec 31, 2015 | ($390.8K) | Mar 30, 2017 |
| FY2015 | Dec 31, 2014 | ($169.7K) | Aug 11, 2016 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $123.1K | Mar 31, 2026 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($235.0K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($69.0K) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($55.5K) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($101.6K) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($75.6K) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($127.0K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($100.0K) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($79.3K) | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | ($59.3K) | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | ($62.3K) | Mar 27, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.8K | Mar 31, 2026 |
| FY2024 | Dec 31, 2024 | $1.2K | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $2.5K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $886 | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $6.3K | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $246.8K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $242.8K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $238.7K | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $234.7K | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $235.3K | Mar 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $170.5K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $169.7K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $91.9K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $27.4K | Mar 22, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($120.7K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($168.5K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($89.5K) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($26.5K) | Mar 28, 2025 |
| FY2023 | Dec 31, 2021 | ($225.6K) | Mar 22, 2024 |
| FY2022 | Dec 31, 2020 | ($1.86M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2019 | ($1.37M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2018 | ($1.08M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2017 | ($856.9K) | Mar 24, 2020 |
| FY2018 | Dec 31, 2016 | ($608.1K) | Mar 27, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.75M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($4.41M) | Mar 31, 2026 |
| FY2024 | Sep 30, 2024 | ($4.41M) | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | ($4.33M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($4.26M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($4.05M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($3.49M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($3.00M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($2.70M) | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | ($2.37M) | Mar 27, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.6K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.2K | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $2.5K | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $886 | Mar 28, 2025 |
| FY2023 | Dec 31, 2021 | $6.0K | Mar 22, 2024 |
| FY2022 | Dec 31, 2020 | $12.6K | Mar 24, 2023 |
| FY2021 | Dec 31, 2019 | $10.5K | Apr 15, 2022 |